{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:38:23Z","timestamp":1794883103663,"version":"4.9.1"},"reference-count":37,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:00:00Z","timestamp":1700265600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","award":["No award\/grant number applicable"],"award-info":[{"award-number":["No award\/grant number applicable"]}],"id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Thorax"],"accepted":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>A post-hoc analysis of the INCREASE trial and its open-label extension (OLE) was performed to evaluate whether inhaled treprostinil has a long-term survival benefit in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Two different models of survival were employed; the inverse probability of censoring weighting (IPCW) and the rank-preserving structural failure time (RPSFT) models both allow construction of a pseudo-placebo group, thereby allowing for long-term survival evaluation of patients with PH-ILD receiving inhaled treprostinil. Time-varying stabilised weights were calculated by fitting Cox proportional hazards models based on the baseline and time-varying prognostic factors to generate weighted Cox regression models with associated adjusted HRs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In the INCREASE trial, there were 10 and 12 deaths in the inhaled treprostinil and placebo arms, respectively, during the 16-week randomised trial. During the OLE, all patients received inhaled treprostinil and there were 29 and 33 deaths in the prior inhaled treprostinil arm and prior placebo arm, respectively. With a conventional analysis, the HR for death was 0.71 (95% CI 0.46 to 1.10; p=0.1227). Both models demonstrated significant reductions in death associated with inhaled treprostinil treatment with HRs of 0.62 (95% CI 0.39 to 0.99; p=0.0483) and 0.26 (95% CI 0.07 to 0.98; p=0.0473) for the IPCW and RPSFT methods, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Two independent modelling techniques that have been employed in the oncology literature both suggest a long-term survival benefit associated with inhaled treprostinil treatment in patients with PH-ILD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/thorax-2023-220821","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T18:20:58Z","timestamp":1700331658000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":21,"title":["Survival analysis from the INCREASE study in PH-ILD: evaluating the impact of treatment crossover on overall mortality"],"prefix":"10.1136","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-1617","authenticated-orcid":false,"given":"Steven D","family":"Nathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Johri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna M","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amresh","family":"Raina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen A","family":"McEvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron B","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,11,18]]},"reference":[{"key":"2025042101250961000_79.4.301.1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1159\/000524263","article-title":"The effect of borderline pulmonary hypertension on survival in chronic lung disease","volume":"101","author":"Piccari","year":"2022","journal-title":"Respiration"},{"key":"2025042101250961000_79.4.301.2","doi-asserted-by":"crossref","first-page":"2045894018775056","DOI":"10.1177\/2045894018775056","article-title":"Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups","volume":"8","author":"Chebib","year":"2018","journal-title":"Pulm Circ"},{"key":"2025042101250961000_79.4.301.3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/resp.14378","article-title":"Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: a Bayesian retrospective observational cohort study","volume":"28","author":"Dawes","year":"2023","journal-title":"Respirology"},{"key":"2025042101250961000_79.4.301.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002110"},{"key":"2025042101250961000_79.4.301.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-9-201305070-00003"},{"key":"2025042101250961000_79.4.301.6","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension: the randomized RISE-IIP study","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025042101250961000_79.4.301.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008470"},{"key":"2025042101250961000_79.4.301.8","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02414-2022","article-title":"Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study","volume":"61","author":"Waxman","year":"2023","journal-title":"Eur Respir J"},{"key":"2025042101250961000_79.4.301.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201311-1951OC"},{"key":"2025042101250961000_79.4.301.10","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2011.592233"},{"key":"2025042101250961000_79.4.301.11","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"key":"2025042101250961000_79.4.301.12","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of Ivosidenib for patients with advanced cholangiocarcinoma with Idh1 mutation: the phase 3 randomized clinical claridhy trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"key":"2025042101250961000_79.4.301.13","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200009000-00012"},{"key":"2025042101250961000_79.4.301.14","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwn164"},{"key":"2025042101250961000_79.4.301.15","doi-asserted-by":"publisher","DOI":"10.1080\/03610929108830654"},{"key":"2025042101250961000_79.4.301.16","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2011.592233"},{"key":"2025042101250961000_79.4.301.17","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19991015)18:19<2617::AID-SIM187>3.0.CO;2-E"},{"key":"2025042101250961000_79.4.301.18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the increase trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025042101250961000_79.4.301.19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.chest.2022.09.007","article-title":"Inhaled treprostinil dose in pulmonary hypertension associated with interstitial lung disease and its effects on clinical outcomes","volume":"163","author":"Nathan","year":"2023","journal-title":"Chest"},{"key":"2025042101250961000_79.4.301.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199111213252103"},{"key":"2025042101250961000_79.4.301.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241201"},{"key":"2025042101250961000_79.4.301.22","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1007\/s12325-022-02253-8","article-title":"Adjusting overall survival estimates of macitentan in pulmonary arterial hypertension after treatment switching: results from the SERAPHIN study","volume":"39","author":"Di Scala","year":"2022","journal-title":"Adv Ther"},{"key":"2025042101250961000_79.4.301.23","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ehjci\/jeac136","article-title":"Right ventricular strain related to pulmonary artery pressure predicts clinical outcome in patients with pulmonary arterial hypertension","volume":"24","author":"\u00dcnl\u00fc","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025042101250961000_79.4.301.24","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.21037\/cdt-20-450","article-title":"Right ventricular dysfunction and long-term risk of death","volume":"10","author":"Sanders","year":"2020","journal-title":"Cardiovasc Diagn Ther"},{"key":"2025042101250961000_79.4.301.25","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/resp.12986","article-title":"Progression of mean pulmonary arterial pressure in idiopathic pulmonary fibrosis with mild to moderate restriction","volume":"22","author":"Teramachi","year":"2017","journal-title":"Respirology"},{"key":"2025042101250961000_79.4.301.26","doi-asserted-by":"publisher","DOI":"10.1159\/000114246"},{"key":"2025042101250961000_79.4.301.27","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2025042101250961000_79.4.301.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199602013340504"},{"key":"2025042101250961000_79.4.301.29","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00003512"},{"key":"2025042101250961000_79.4.301.30","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2025042101250961000_79.4.301.31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.rmed.2019.04.016","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment","volume":"153","author":"Nathan","year":"2019","journal-title":"Respiratory Medicine"},{"key":"2025042101250961000_79.4.301.32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with Nintedanib: pooled data from six clinical trials","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2025042101250961000_79.4.301.33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273854","article-title":"Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone","volume":"17","author":"M\u00e1jek","year":"2022","journal-title":"PLoS ONE"},{"key":"2025042101250961000_79.4.301.34","doi-asserted-by":"crossref","unstructured":"Gao J , Kalafatis D , Carlson L , et al . Baseline characteristics and survival of patients of idiopathic pulmonary fibrosis: a longitudinal analysis of the Swedish IPF registry. Respir Res 2021;22. doi:10.1186\/s12931-021-01634-x","DOI":"10.1186\/s12931-021-01634-x"},{"key":"2025042101250961000_79.4.301.35","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019"},{"key":"2025042101250961000_79.4.301.36","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-021-01783-1","article-title":"Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (Ipf) and non-IPF: a systematic review and meta-analysis","volume":"21","author":"Finnerty","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025042101250961000_79.4.301.37","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.chest.2021.06.049","article-title":"Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"160","author":"Petnak","year":"2021","journal-title":"Chest"}],"container-title":["Thorax"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/thorax-2023-220821","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:59:41Z","timestamp":1745233181000},"score":1,"resource":{"primary":{"URL":"https:\/\/thorax.bmj.com\/lookup\/doi\/10.1136\/thorax-2023-220821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,18]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,15]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/thorax-2023-220821"],"URL":"https:\/\/doi.org\/10.1136\/thorax-2023-220821","relation":{},"ISSN":["0040-6376","1468-3296"],"issn-type":[{"value":"0040-6376","type":"print"},{"value":"1468-3296","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,18]]}}}